Skip to content
Adam Torkildson – Lifestyle
Author:
Vera Therapeutics
Vera Therapeutics to Participate at Upcoming Investor Conferences
September 1, 2026
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
August 10, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
July 9, 2026
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
July 7, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
June 2, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2026
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 8, 2026
1
2
Next Page
→